Oldham R K, Foon K A, Morgan A C, Woodhouse C S, Schroff R W, Abrams P G, Fer M, Schoenberger C S, Farrell M, Kimball E
J Clin Oncol. 1984 Nov;2(11):1235-44. doi: 10.1200/JCO.1984.2.11.1235.
The murine antimelanoma monoclonal antibody, 9.2.27, was administered intravenously to eight patients with metastatic malignant melanoma. Biopsies of metastatic nodules clearly demonstrate the selective localization of this antibody on the melanoma cell surface with a dose-response relationship to the quantity of administered antibody. The antibody infusions were clinically well tolerated and the pharmacokinetics of the antibody and the antiglobulin responses are described. This study indicates that murine monoclonal antibodies have potential as selective targeting agents in the design of future therapeutic trials using monoclonal antibodies or conjugates thereof in the treatment of cancer.
将鼠抗黑色素瘤单克隆抗体9.2.27静脉注射给8例转移性恶性黑色素瘤患者。转移性结节的活检清楚地表明，该抗体在黑色素瘤细胞表面选择性定位，且与所给予抗体的量呈剂量反应关系。抗体输注在临床上耐受性良好，并描述了抗体的药代动力学和抗球蛋白反应。本研究表明，在未来使用单克隆抗体或其缀合物治疗癌症的治疗试验设计中，鼠单克隆抗体有作为选择性靶向剂的潜力。
